Search Results - Wayne P. Rothbaum

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF) by Michael Gulrajani, Tracy Clevenger, Jean Cheung, Fanny Krantz, Cynthia Nguyen, Miranda Luarca, Cecile Krejsa, Wayne P. Rothbaum, Todd Covey

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  2. 2

    P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF) by Tracy Clevenger, Jean Cheung, Fanny Krantz, Michael Gulrajani, Cynthia Nguyen, Miranda Luarca, Cecile Krejsa, Wayne P. Rothbaum, Todd Covey

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  3. 3

    P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING by Subbaiah Chary Nimmagadda, Paulina Marie Budde, Kaiyan Sun, Todd Covey, Cecile Krejsa, Wayne P. Rothbaum, Nikolas von Bubnoff, Cyrus Khandanpour

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  4. 4

    PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS)... by Francesca Palandri, Stefanie Gröpper, Michael Loschi, Marcelo Bellesso, Sebastian Grosicki, Pilar Giraldo, Claire Harrison, Tracy Clevenger, Nikki Stuart, Hope Qamoos, Gregory Vosganian, Wayne P. Rothbaum, Srdan Verstovsek, Pankit Vachhani

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  5. 5

    P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPH... by John C. Byrd, Seema Ali Bhat, Farrukh Awan, Pratyush Giri, Sumita Ratnasingam, Roman Hájek, Dagmar Hess, Daniela Alves, Jan Maciej Zaucha, Annalise Shen, Elizabeth Bilotti, Jesse Mcgreivy, Wayne P. Rothbaum, Hanna Ciepluch

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  6. 6

    P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PL... by Michael Loschi, Laszlo Rejto, Hun Chuah, Marianna Caramella, Jesus Hernández Rivas, Paolo Sportoletti, Viviane Dubruille, Marcelo Bellesso, Stefanie Gröpper, Carl Crodel, Hope Qamoos, Ashley Socotch, Zhuying Huang, Sarah Wall, Jesse Mcgreivy, Wayne P. Rothbaum, Srdan Verstovsek, Francesca Palandri

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  7. 7

    S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (... by Pankit Vachhani, Andrew Perkins, John Mascarenhas, Haifa Kathrin Al-Ali, Jean-Jacques Kiladjian, Sonia Cerquozzi, Jaroslaw Dybko, Regina Garcia Delgado, Jesus Hernández Rivas, Holger Hebart, Zhuying Huang, Cecile Krejsa, Hope Qamoos, Jesse Mcgreivy, Wayne P. Rothbaum, Srdan Verstovsek, Alessandro Vannucchi

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  8. 8

    S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIM... by John Mascarenhas, Tania Jain, Salman Otoukesh, Aaron T. Gerds, Alessandro Lucchesi, Iberia Romina Sosa, Kamel Laribi, Elena Mishchenko, Atanas Radinoff, Giulia Benevolo, Alessandro M. Vannucchi, Francoise Boyer, Philippe Quittet, Markus Radsak, Antoine Machet, Prithviraj Bose, Zhuying Huang, Hope Qamoos, Jesse Mcgreivy, Wayne P. Rothbaum, Srdan Verstovsek, Francesco Passamonti

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


Search Tools: